NCT03251924 2023-02-28A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsBristol-Myers SquibbPhase 1/2 Terminated80 enrolled 33 charts